Technical Analysis for VERV - Verve Therapeutics, Inc.

Grade Last Price % Change Price Change
B 63.85 3.42% 2.11
VERV closed up 3.42 percent on Wednesday, August 4, 2021, on 54 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up
Historical VERV trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Upper Bollinger Band Walk Strength 3.42%
Wide Bands Range Expansion 3.42%
Overbought Stochastic Strength 3.42%
Upper Bollinger Band Touch Strength 3.42%
New 52 Week Closing High Bullish -2.00%
Older End-of-Day Signals for VERV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 17 hours ago
Up 1 ATR about 20 hours ago
60 Minute Opening Range Breakout about 21 hours ago
Rose Above Upper Bollinger Band about 21 hours ago
Up 5% about 21 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Verve Therapeutics, Inc. Description

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Cholesterol Hypercholesterolemia Lipids Low Density Lipoprotein Chronic Management

Is VERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 73.8
52 Week Low 29.5
Average Volume 521,958
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 53.29
10-Day Moving Average 57.11
Average True Range 5.85
ADX 48.53
+DI 34.89
-DI 8.14
Chandelier Exit (Long, 3 ATRs) 50.93
Chandelier Exit (Short, 3 ATRs) 62.76
Upper Bollinger Bands 64.48
Lower Bollinger Band 42.09
Percent B (%b) 0.97
BandWidth 42.01
MACD Line 4.90
MACD Signal Line 3.88
MACD Histogram 1.0172
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 73.32
Resistance 3 (R3) 73.52 70.56 71.74
Resistance 2 (R2) 70.56 68.15 70.46 71.22
Resistance 1 (R1) 67.21 66.66 68.89 67.01 70.69
Pivot Point 64.25 64.25 65.09 64.15 64.25
Support 1 (S1) 60.89 61.84 62.57 60.69 57.01
Support 2 (S2) 57.93 60.35 57.83 56.48
Support 3 (S3) 54.58 57.93 55.96
Support 4 (S4) 54.38